Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)

• Status: Not yet recruiting
• Trial end date: 2024-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to evaluate the colchicine protective effect in patients undergoing Percutaneous Coronary Intervention (PCI). The main question it aims to answer is: does initiating colchicine before planned PCI will reduce post-procedural myocardial injury? Half of the participants will receive colchicine, while the other half will receive a placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Helwan University
• Treatments: Colchicine

Criteria

Inclusion Criteria:

• Chronic Coronary Syndrome (CCS) participants referred for PCI.

• Acute Coronary Syndrome (ACS) participants who are medically treated or undergoing revascularization for non-culprit lesions will be included if their troponin I and hs-CRP returned back to normal baseline

Exclusion Criteria:

• Acute Coronary Syndrome (ACS) participants.

• Chronic kidney disease (glomerular filltration rate <30 ml/ min).

• Participants with history of cirrhosis.

• Participants on systemic immunosuppressive or corticosteroid therapy.

• Active malignancy or infection.

• Elevated troponin I.